LOS ANGELES--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company with products for the treatment of Xerostomia, dermatological conditions, and acute respiratory diseases, announced today that it has entered into an agreement to acquire the exclusive U.S. rights to a novel product for hair loss developed by Laboratories Carilene, a French-based developer of therapeutic products, including Aquoral™ which Auriga currently distributes. The new product will be available without a prescription and promoted through the Company’s Consumer Brands division. Currently, this formulation is available in Europe where it has sold over 2 million units since its introduction.
